The potassium salt of 4,5-dihydro-2-(6-hydroxy-2-benzothiazolyl)-4-thiazolecarboxylic acid, systematically designated as D-luciferin potassium salt (CAS
103404-75-7), functions as the native heterocyclic substrate for recombinant firefly luciferase (Photinus pyralis, EC 1.13.12.7). The compound is supplied as a lyophilized, free-flowing powder with a color range from pale yellow to light brown. Chromatographic purity determined by reversed-phase HPLC with UV detection at
330 nm consistently exceeds
99% area normalization, and enantiomeric excess of the D-isomer is verified at ≥
99.5% via chiral stationary-phase analysis. The molecular formula C₁₁H₇N₂KO₃S₂ corresponds to a formula weight of
318.4 g·mol⁻¹, and the product is routinely offered in aliquots of
10 mg,
50 mg, and
1 g sealed under argon.
Chemical Identity and Lot-Release Specifications
Lot-to-lot consistency is controlled through a panel of compendial and instrumental methods. Particulate water content, determined by Karl Fischer coulometry (following Ph. Eur. 2.5.12), remains below
0.5% (w/w) for freshly opened containers. The heavy metals limit is set at ≤
10 ppm as lead, tested per USP <231>. Residual solvents are quantified by headspace GC-FID; acetone and ethanol are individually maintained below
500 ppm. A full absorption spectrum in
50 mM Tris-acetate buffer, pH
7.8, shows λmax at
328 nm (ε =
18,200 M⁻¹·cm⁻¹), with an A
280/A
330 ratio of
1.15 ± 0.05. Bioburden is controlled at ≤
10 CFU/g (membrane filtration, TSA/SDA,
30–35°C). Every production lot is tested in a luciferase luminescence assay (Promega Luciferase Assay System) against an in-house reference standard; relative specific activity must fall within
95%–105%.
| Parameter | Typical Value | Method |
|---|
| Assay (anhydrous basis) | ≥99.0% | HPLC, 330 nm, C18 column |
| Enantiomeric purity | ≥99.5% D-isomer | Chiral HPLC |
| Water content | ≤0.5% | KF coulometry |
| Solubility in water (25°C) | ≥20 mg·mL⁻¹ | Visual, vortex dissolution 1 min |
| Residue on ignition | 26.0%–28.5% | 600°C / 2 h |
| Bioburden | ≤10 CFU/g | Membrane filtration |
Application in ATP bioluminescence quantification is direct: a working solution of the potassium salt at
1 mM in
50 mM HEPES,
10 mM MgSO₄,
1 mM DTT, pH
7.5, is mixed with recombinant luciferase and sample ATP in a white 96-well microplate. Light output measured on a Berthold Centro XS³ LB 960 luminometer over a
10-second integration window yields a linear response from
1 × 10⁻¹³ to
1 × 10⁻⁸ moles ATP per well (r² >
0.998). The lower limit of detection, calculated as three standard deviations above background, routinely falls at
0.05 pg ATP (
9.1 × 10⁻¹⁴ mol) when a stabilized luciferase variant with 0.5 U·mL⁻¹ final activity is employed. This performance envelope meets the sensitivity requirements of ASTM E2694-21 for adenosine triphosphate in water and is compatible with the hygiene monitoring schemes of ISO 22000:2018 food safety management systems.
What Distinguishes the Potassium Salt from Free Acid and Alternative Salts?
The free acid form of D-luciferin (CAS
2591-17-5) exhibits a carboxyl pKa of approximately
4.5, rendering it sparingly soluble in neutral aqueous buffers unless pre-neutralized with a strong base. Direct hydration of the free acid typically requires dropwise addition of
0.5 M NaOH under stirring, a step that introduces operator-dependent variability in pH and can produce local alkaline hot spots that accelerate oxidative degradation of the benzothiazole ring. The potassium salt bypasses this preparation sequence entirely: dissolution in
50–100 mM Tris or HEPES buffer at
20–25°C proceeds to completion within
60 seconds of gentle vortexing, yielding a clear, faintly yellow solution at pH
7.5 ± 0.2 with no residual particulate. This property is particularly advantageous in high-throughput screening environments where robotic liquid handlers dispense substrate stocks across numerous plates over several hours; the reduced handling time and elimination of pH equilibration steps minimize signal drift.
A sodium salt variant (CAS
103404-76-8) is also commercially available, yet the potassium salt is often preferred when the luciferase reaction buffer is formulated with potassium-based salts to maintain intracellular-like ionic conditions. Firefly luciferase exhibits a slight but reproducible increase in turnover number in the presence of
100 mM K⁺ versus equimolar Na⁺, attributed to cation-dependent conformational stabilization of the C-terminal domain. Direct substitution of the potassium salt for the sodium salt therefore circumvents the introduction of incompatible counterions, preserving maximal luminescence flux in integration times as short as
100 ms. L-luciferin, the enantiomer, is not merely inert; concentrations above
50 µM act as a competitive inhibitor with a Kᵢ of
11.2 µM for Photinus pyralis luciferase. For this reason, enantiomeric excess exceeding
99.5% is mandatory, and potassium salt lots are rejected if chiral HPLC reveals more than
0.2% L-isomer.
| Property | Potassium Salt | Free Acid | Sodium Salt |
|---|
| Aqueous solubility (25°C) | ≥20 mg·mL⁻¹ | ≤2 mg·mL⁻¹ without base | ≥25 mg·mL⁻¹ |
| Pre-dissolution pH of 1 mM solution | 7.5 ± 0.2 | 3.1 ± 0.2 | 7.6 ± 0.2 |
| Relative light units (RLU) per µmole substrate* | 1.02 ± 0.03 | 1.00 (reference) | 0.96 ± 0.04 |
| Recommended cation in luciferase buffer | K⁺ | — | Na⁺ |
| Oxidative degradation t₉₀ (aerobic, 25°C) | 4.2 h | 3.8 h after neutralization | 4.0 h |
*RLU normalized to free-acid luciferin measured on a GloMax® Navigator (Promega) in 25 mM Tricine, 5 mM MgSO₄, 1 mM DTT, 2 mM ATP, pH 7.8, 25°C.
When Microcentrifuge Tube Bioluminescence Imaging Requires Pre-formulated Substrate Stocks
Investigators performing in vivo bioluminescence imaging (BLI) on small rodent models often reconstitute the substrate at
15 mg·mL⁻¹ in sterile Dulbecco’s phosphate‑buffered saline (DPBS; Ca²⁺- and Mg²⁺-free) immediately before intraperitoneal injection. The potassium salt’s rapid dissolution and near-neutral pH reduce peritonitic irritation compared to neutralized free acid solutions that can retain transient alkalinity. Stock solutions filtered through a
0.22 µm PVDF syringe filter and stored in single-use amber vials at
−80°C retain
>95% of original luminescence-generating activity after
30 days, as verified by a dual-replicate ATP standard curve using recombinant luciferase (QuantiLum recombinant luciferase, Promega). Multiple freeze-thaw cycles degrade signal intensity by approximately
12% per cycle, so single-use aliquots are mandatory for reproduction of quantitative BLI data within
CV ≤ 8%.
In cell-based ATP viability assays following ISO 10993-5 for medical device cytotoxicity, the potassium salt is dissolved at
2 mM in pre-warmed (37°C) culture medium without serum and combined with luciferase and cell lysate in opaque-walled plates. The initial luminescence half-life under these conditions measures
5.3 minutes due to endogenous ATPases; consequently, luminometer injection modules configured with dual-syringe pumps dispensing substrate- and enzyme-containing reagent in a
100 µL total volume per well are recommended to achieve a coefficient of variation below
3% across triplicate wells. Plate layout designs should incorporate ATP standards in quadruplicate, a background control consisting of lysed medium without cells, and a positive lysis control exposed to
0.1% Triton X-100.
Operational boundaries are critical: the potassium salt is incompatible with buffer systems containing
≥0.02% sodium azide, as azide reacts with luciferin under ambient light to form non-emissive adducts within
15 minutes. Stock solutions must be protected from direct fluorescent lighting and maintained in amber glass or opaque polypropylene containers. Additionally, D-luciferin potassium salt should not be co-stored with amine-containing lyophilization bulking agents such as Tris base in dry powder premixes; sublimation during prolonged storage at
–20°C can promote Maillard-type browning, yielding visible discoloration and a loss of luciferin content exceeding
25% over
12 months. When these constraints are observed, the product provides a reproducible substrate source for luciferase-based analytical methods spanning environmental hygiene monitoring, gene reporter quantitation, and preclinical imaging.
